EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?

Edmund Y M Chung iD, Sunil V Badve, Hiddo J L Heerspink, Muh Geot Wong iD

Nephrology · 2023-02 · 28 (2) · 97-108

DOI: 10.1111/nep.14130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology, online erschienen am 15.11.2022. Verfasst von Edmund Y M Chung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Renal Insufficiency, Chronic, Diabetes Mellitus. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global prevalence of diabetes mellitus and hypertension. While renin angiotensin system inhibitors and sodium‐glucose cotransporter two inhibitors are the management cornerstone for reducing kidney and cardiovascular complications in patients with diabetic and non‐diabetic kidney disease (DKD), they are partially effective and further treatments are needed to prevent the progression to kidney failure. Endothelin receptor antagonism represent a potential additional therapeutic option due to its beneficial effect on pathophysiological processes involved in progressive kidney disease including proteinuria, which are independently associated with progression of kidney disease. This review discusses the biological mechanisms of endothelin receptor antagonists (ERA) in kidney protection, the efficacy and safety of ERA in randomised controlled trials reporting on kidney outcomes, and its potential future use in both diabetic and non‐DKDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesRenal Insufficiency, ChronicDiabetes MellitusHumansEndothelin Receptor AntagonistsKidneyAntihypertensive AgentsAngiotensin Receptor Antagonists

Stichwörter der Autor:innen

chronic kidney diseaseendothelinfluid retentionkidney failureproteinuria

Substanzen

Endothelin Receptor AntagonistsAntihypertensive AgentsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
  • Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales, Newtown, New South Wales, Australia.
  • Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia.
  • Department of Clinical Pharmacoy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Department of Renal Medicine, Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia.

ORCID-Profile: Edmund Y M Chung, Muh Geot Wong

Zitieren

APA

Chung, E. Y. M., Badve, S. V., Heerspink, H. J. L., & Wong, M. G. (2023). Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?. Nephrology, 28(2), 97-108. https://doi.org/10.1111/nep.14130

Vancouver

Chung EYM, Badve SV, Heerspink HJL, Wong MG. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?. Nephrology. 2023;28(2):97-108. doi:10.1111/nep.14130

BibTeX
@article{Chung2023,
  author = {Chung, Edmund Y M and Badve, Sunil V and Heerspink, Hiddo J L and Wong, Muh Geot},
  title = {Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?},
  journal = {Nephrology},
  year = {2023},
  volume = {28},
  number = {2},
  pages = {97--108},
  doi = {10.1111/nep.14130}
}
Kostenlos starten →